US FDA takes key actions for bulk drugs used for compounding

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1713卷 / 1期

关键词：

D O I：

10.1007/s40278-018-49838-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：4 / 4

相关论文

共 50 条

[21] Pharmaceuticals - US FDA unease over two drugs
不详
EUROPEAN CHEMICAL NEWS, 1997, 68 (1779): : 5 - 5
[22] A Survey of the Structures of US FDA Approved Combination Drugs
Das, Pradipta
Delost, Michael D.
Qureshi, Munaum H.
Smith, David T.
Njardarson, Jon T.
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (09) : 4265 - 4311
[23] US FDA cuts time to get drugs to market
不详
EUROPEAN CHEMICAL NEWS, 1996, 65 (1709): : 4 - 4
[24] DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA
Lesko, Lawrence J.
Zineh, Issam
PHARMACOGENOMICS, 2010, 11 (04) : 507 - 512
[25] US FDA and DCRI to collaborate on cardiac safety of drugs
Reactions Weekly, 2006, 1122 (1) : 2 - 2
[26] HOW THE FDA DETERMINES THE SAFETY OF DRUGS - ARE DRUGS USED IN OBSTETRICS REALLY SAFE
HAIRE, D
JOURNAL OF NURSE-MIDWIFERY, 1982, 27 (02): : 28 - 32
[27] ANALYTICAL PROCEDURES USED IN FDA LABORATORIES FOR ANALYSIS OF HALUCINOGENIC DRUGS
MARTIN, RJ
ALEXANDER, TG
JOURNAL OF THE ASSOCIATION OF OFFICIAL ANALYTICAL CHEMISTS, 1968, 51 (01): : 159 - +
[28] FDA to require pediatric studies for drugs commonly used in children
不详
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1999, 56 (03) : 203 - 203
[29] FDA review practices and priorities for drugs used in cancer treatment
Kobayashi, K
DeLap, RJ
SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS), 2001, 949 : 341 - 344
[30] Regulatory Impact of Selected US FDA Postmarketing Safety Registries Conducted for Drugs Used to Treat Inflammatory or Autoimmune Conditions
Guiriansoro, Zakaridja
Oussova, Tatiana
Weissfeld, Joel
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (12)

← 1 2 3 4 5 →